36 articles in this topic
Researchers at Assiut University investigated whether COVID-19 infection triggers serious blood disorders including aplastic anemia and immune cytopenias.
A Phase II pilot trial tests whether adding carfilzomib to plasma exchange and IVIG can safely reverse antibody-mediated rejection after lung transplantation.
A Phase 1 trial evaluates DNA and protein HIV vaccines given alone or together to assess safety and immune response in healthy adults.
A completed trial tests whether diode laser treatment reduces TLR-4 in saliva, linking periodontal inflammation to systemic aging biology.
A completed French trial investigated whether rogue antibodies targeting ghrelin and alpha-MSH disrupt appetite regulation in eating disorder patients.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
Researchers tested whether eosinophil β1 integrin activation in blood could track disease activity, potentially sparing patients repeat invasive procedures.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
A Phase 1 pilot trial explores whether the IL-12/23 blocker ustekinumab is safe and can reduce systemic inflammation in Sjögren's patients.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
A large global Phase III trial evaluated the efficacy, safety, and immunogenicity of CanSino's adenovirus-vectored COVID-19 vaccine across 44,247 adults.
